

Amended claims as attached to the IPER

5

Patent Claims

1. Use of bromelaine proteases for inhibiting blood coagulation, wherein the bromelaine
10 proteases are selected from the group consisting of:

a) a basic bromelaine protease, having

- a molecular weight of about 24.4 KDa,
- an optimal activity at a pH in the range of 4 to 5.5, and
- 15 - comprising the following amino acid sequence:

Val Pro Gln Ser Ile Asp Trp Arg Asp Tyr
Gly Ala Val Thr Ser Val Lys Asn Gln Asn

20 and/or

b) a basic bromelaine protease, having

- a molecular weight of about 24.5 KDa,
- an optimal activity at a pH in the range of 3.5 to 5, and
- 25 - comprising the following amino acid sequence:

Val Pro Gln Ser Ile Asp Trp Arg Asp Tyr
Gly Ala Val Thr Ser Val Lys Asn Gln Asn

and/or

30 c) a basic bromelaine protease, having

- a molecular weight of about 23.4 KDa,
- an optimal activity at a pH in the range of 6 to 8, and
- comprising the following amino acid sequence:

Val Pro Gln Ser Ile Asp Trp Arg Asp Ser
Gly Ala Val Thr Ser Val Lys Asn Gln Gly.

6.1.1

2. Use according to claim 1, wherein the plasmin production is stimulated.

5

3. Use according to claim 1, wherein the production of fibrin is inhibited.

4. Use according to claim 1, wherein the adhesion of thrombocytes on endothelium cells is inhibited.

10

5. Medicament for inhibiting blood coagulation, wherein the medicament, apart from conventional excipients and auxiliary substances, consists of one or more bromelaine proteases according to claim 1.

15

6. Medicament according to claim 5, wherein the bromelaine protease is a recombinant bromelaine protease.

add B7